Diagnostic Significance of Dual Immunocytochemical Staining of P53/cytokeratin20 on Liquid-based Urine Cytology to Detect Urothelial Carcinoma

Overview

Journal Cytojournal

Date 2020 Apr 8

PMID 32256669

Citations 4

Authors

Song-Yi Choi

Kyung-Hee Kim

Kwang-Sun Suh

Min-Kyung Yeo

Affiliations

Soon will be listed here.

Abstract

Background: Urine cytology is a noninvasive and inexpensive method; however, it is limited in low sensitivity for detecting and monitoring urothelial carcinoma (UC). To overcome limitation of cytology, several tests using urine samples have been attempted that immunocytochemical staining is an inexpensive and easy to perform ancillary technique. Dual immunocytochemical staining for p53 and cytokeratin 20 (CK20) is assessed in liquid-based urine cytology slides.

Materials And Methods: Liquid-based urine cytology samples collected between 2008 and 2013 and matched follow-up biopsy samples of high-grade UC (HGUC) ( = 44) and low-grade UC (LGUC) ( = 14) were analyzed.

Results: Urine cytology showing atypical cells was subjected to dual-color immunostaining for p53 and CK20. The sensitivity of urine cytology combined with p53 and CK20 immunostaining was 77.3% in HGUC and 52.9% in LGUC. Of 20 cases diagnosed with atypia by urine cytology, 13 (65%) were positive for p53 or CK20. Dual immunocytochemical staining for p53/CK20 improved the diagnostic accuracy of urine cytology.

Conclusions: The present results indicate that cytomorphology combined with p53/CK20 immunostaining is useful for the detection of HGUC and LGUC.

Citing Articles

Diagnostic Significance of Cytokeratin 20 and p53 as Adjunct Immunocytological Markers in Urine Cytology to Detect Urothelial Carcinomas: A Systematic Review Study.

Angel E Iran J Pathol. 2023; 18(3):257-269.

PMID: 37942190 PMC: 10628378. DOI: 10.30699/IJP.2023.1972203.3004.

MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.

Kobayashi G, Hayashi T, Sentani K, Uraoka N, Fukui T, Kido A Diagn Pathol. 2023; 18(1):106.

PMID: 37737200 PMC: 10515259. DOI: 10.1186/s13000-023-01392-y.

p53 expression in repair/reactive renal tubular cells: A potential pitfall leading to a false-positive diagnosis of urine cytology.

Enomoto K, Matsunaga T, Sofue T, Nakamura A, Hirakawa E, Ibuki E Cancer Med. 2021; 10(24):8846-8853.

PMID: 34783171 PMC: 8683536. DOI: 10.1002/cam4.4389.

Cell-blocks and immunohistochemistry.

Shidham V, Layfield L Cytojournal. 2021; 18:2.

PMID: 33598043 PMC: 7881511. DOI: 10.25259/Cytojournal_83_2020.

References

Bostwick D, Hossain D . Does subdivision of the "atypical" urine cytology increase predictive accuracy for urothelial carcinoma?. Diagn Cytopathol. 2014; 42(12):1034-44. DOI: 10.1002/dc.23159. View

Harnden P, Eardley I, Joyce A, Southgate J . Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol. 1996; 78(6):870-5. DOI: 10.1046/j.1464-410x.1996.23511.x. View

Halder S, Dey R, Chowdhury A, Bhattacharyya P, Chakrabarti A . Differential regulation of urine proteins in urothelial neoplasm. J Proteomics. 2015; 127(Pt A):185-92. DOI: 10.1016/j.jprot.2015.04.022. View

Eissa S, Swellam M, Amin A, Balbaa M, Yacout G, El-Zayat T . The clinical relevance of urine-based markers for diagnosis of bladder cancer. Med Oncol. 2011; 28(2):513-8. DOI: 10.1007/s12032-010-9422-6. View

Nu T, Kassouf W, Ahmadi-Kaliji B, Charbonneau M, Auger M, Brimo F . The value of the "suspicious for urothelial carcinoma" cytology category: a correlative study of 4 years including 337 patients. Cancer Cytopathol. 2014; 122(11):796-803. DOI: 10.1002/cncy.21449. View

Mallofre C, Castillo M, Morente V, Sole M . Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia. Mod Pathol. 2003; 16(3):187-91. DOI: 10.1097/01.MP.0000056628.38714.5D. View

Harnden P, Mahmood N, Southgate J . Expression of cytokeratin 20 redefines urothelial papillomas of the bladder. Lancet. 1999; 353(9157):974-7. DOI: 10.1016/S0140-6736(98)05383-5. View

Li H, Li M, Li C, Ma J, Wang M, Rao J . ImmunoCyt and cytokeratin 20 immunocytochemistry as adjunct markers for urine cytologic detection of bladder cancer: a prospective study. Anal Quant Cytol Histol. 2010; 32(1):45-52. View

Mbeutcha A, Lucca I, Mathieu R, Lotan Y, Shariat S . Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer. Urol Clin North Am. 2015; 43(1):47-62. DOI: 10.1016/j.ucl.2015.08.005. View

10.

McCroskey Z, Pambuccian S, Kleitherms S, Antic T, Cohen M, Barkan G . Accuracy and interobserver variability of the cytologic diagnosis of low-grade urothelial carcinoma in instrumented urinary tract cytology specimens. Am J Clin Pathol. 2015; 144(6):902-8. DOI: 10.1309/AJCPE1O9YKMRSQKG. View

11.

Soyuer I, Sofikerim M, Tokat F, Soyuer S, Ozturk F . Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression. Diagn Pathol. 2009; 4:20. PMC: 2709650. DOI: 10.1186/1746-1596-4-20. View

12.

Srivastava R, Arora V, Aggarwal S, Bhatia A, Singh N, Agrawal V . Cytokeratin-20 immunocytochemistry in voided urine cytology and its comparison with nuclear matrix protein-22 and urine cytology in the detection of urothelial carcinoma. Diagn Cytopathol. 2012; 40(9):755-9. DOI: 10.1002/dc.21617. View

13.

Anderlini R, Manieri G, Lucchi C, Raisi O, Soliera A, Torricelli F . Automated urinalysis with expert review for incidental identification of atypical urothelial cells: An anticipated bladder carcinoma diagnosis. Clin Chim Acta. 2015; 451(Pt B):252-6. DOI: 10.1016/j.cca.2015.10.005. View

14.

Bohm M, Schostak M, Hakenberg O . Urinary immunocytology--promise or nonseller? A review with an opinion. Urol Oncol. 2014; 32(4):383-90. DOI: 10.1016/j.urolonc.2013.11.002. View

15.

Kumar P, Nandi S, Tan T, Ler S, Chia K, Lim W . Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma. Oncotarget. 2015; 6(15):13539-49. PMC: 4537032. DOI: 10.18632/oncotarget.3841. View

16.

Wegelin O, Bartels D, Tromp E, Kuypers K, van Melick H . The Effects of Instrumentation on Urine Cytology and CK-20 Analysis for the Detection of Bladder Cancer. Urology. 2015; 86(4):772-6. DOI: 10.1016/j.urology.2015.06.035. View

17.

Fowler L, Lachar W . Application of immunohistochemistry to cytology. Arch Pathol Lab Med. 2008; 132(3):373-83. DOI: 10.5858/2008-132-373-AOITC. View

18.

Lin S, Hirschowitz S, Williams C, Shintako P, Said J, Rao J . Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: preliminary retrospective study on archived urine slides. Cancer Detect Prev. 2001; 25(2):202-9. View

19.

McKenney J, Desai S, Cohen C, Amin M . Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol. 2001; 25(8):1074-8. DOI: 10.1097/00000478-200108000-00013. View

20.

Hajdinjak T . UroVysion FISH test for detecting urothelial cancers: meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol Oncol. 2008; 26(6):646-51. DOI: 10.1016/j.urolonc.2007.06.002. View